[go: up one dir, main page]

ATE435302T1 - Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken - Google Patents

Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Info

Publication number
ATE435302T1
ATE435302T1 AT03747881T AT03747881T ATE435302T1 AT E435302 T1 ATE435302 T1 AT E435302T1 AT 03747881 T AT03747881 T AT 03747881T AT 03747881 T AT03747881 T AT 03747881T AT E435302 T1 ATE435302 T1 AT E435302T1
Authority
AT
Austria
Prior art keywords
rivastigmine
determination
treatment success
apoe genotype
predicting treatment
Prior art date
Application number
AT03747881T
Other languages
English (en)
Inventor
Roger Lane
Mihael Polymeropoulos
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE435302T1 publication Critical patent/ATE435302T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775Apolipopeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AT03747881T 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken ATE435302T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
ATE435302T1 true ATE435302T1 (de) 2009-07-15

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747881T ATE435302T1 (de) 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Country Status (14)

Country Link
US (3) US20060160079A1 (de)
EP (1) EP1529116B1 (de)
JP (1) JP2005534710A (de)
CN (1) CN1681941A (de)
AT (1) ATE435302T1 (de)
AU (1) AU2003266967B2 (de)
BR (1) BR0313588A (de)
CA (1) CA2494585A1 (de)
DE (1) DE60328198D1 (de)
DK (1) DK1529116T3 (de)
ES (1) ES2327914T3 (de)
IL (1) IL166466A0 (de)
PT (1) PT1529116E (de)
WO (1) WO2004015140A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
CA2596523A1 (en) * 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
PT2179284T (pt) 2007-07-31 2016-12-30 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN105640931A (zh) 2008-07-03 2016-06-08 艾克塞拉公司 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2018175581A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
HRP20210634T1 (hr) 2017-05-24 2021-05-28 H. Lundbeck A/S Kombinacija 5-ht6 antagonist receptora i inhibitora acetilkolinesteraze za uporabu u liječenju alzheimerove bolesti u subpopulaciji pacijenta koji nosi apoe4 alela
US20210195879A1 (en) * 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
EP3931349B8 (de) * 2019-02-28 2025-01-15 The Rockefeller University Apoe-genotyping in der krebsprognose und -therapie
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
CN117886933A (zh) * 2023-12-28 2024-04-16 上海良润生物医药科技有限公司 一种载脂蛋白e检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE625212T1 (de) * 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインe4特異モノクローナル抗体
HUP0103883A3 (en) * 1998-10-01 2002-11-28 Novartis Ag New sustained release oral formulations
ATE314343T1 (de) * 2000-06-30 2006-01-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
US20100240744A1 (en) 2010-09-23
BR0313588A (pt) 2005-07-12
DE60328198D1 (de) 2009-08-13
ES2327914T3 (es) 2009-11-05
CA2494585A1 (en) 2004-02-19
IL166466A0 (en) 2006-01-15
JP2005534710A (ja) 2005-11-17
US20080214662A1 (en) 2008-09-04
EP1529116A1 (de) 2005-05-11
PT1529116E (pt) 2009-09-10
AU2003266967A1 (en) 2004-02-25
US20060160079A1 (en) 2006-07-20
EP1529116B1 (de) 2009-07-01
AU2003266967B2 (en) 2006-11-16
CN1681941A (zh) 2005-10-12
WO2004015140A1 (en) 2004-02-19
DK1529116T3 (da) 2009-11-09

Similar Documents

Publication Publication Date Title
ATE435302T1 (de) Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
ATE503563T1 (de) Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren
DE602005023517D1 (de) Verfahren zur bestimmung von genotoxizität
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
ATE469245T1 (de) Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
DE602005023363D1 (de) Vorrichtung und Verfahren zur Authentifizierung von Blutgefässen
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2006053252A3 (en) Methods of treating hematological malignancies with nucleoside analog drugs
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1529116

Country of ref document: EP

REN Ceased due to non-payment of the annual fee